Is Starlink Set For The Largest IPO In History?

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!

John Connaughton net worth and biography

John Connaughton Biography and Net Worth

Director of IQVIA

John P. Connaughton has served as a director of IQVIA since October 2016. Prior to this, Mr. Connaughton served as a director of Quintiles since January 2008. Since 1997, Mr. Connaughton has been a Managing Director of Bain Capital. Prior to Bain Capital, which he joined in 1989, Mr. Connaughton was a consultant at Bain & Company, Inc., where he worked in the healthcare, consumer products and business services industries. He also serves as a director of iHeartMedia, Inc., a global media and entertainment company, Air Medical Group Holdings, Inc., a provider of air medical services, Bio Products Laboratory, a United Kingdom based producer of plasma products, Grupo Notre Dame Intermedica, a Brazil based healthcare provider, and The Boston Celtics, a National Basketball Association franchise. Mr. Connaughton was formerly a director of SunGard Data Systems Inc., a software and technology services company, Warner Music Group Corp., a music based content company, Warner Chilcott plc, an international pharmaceutical company, HCA Holdings, Inc., a corporate operator of hospitals and health systems, and CRC Health Corporation, a provider of treatment and educational programs related to behavioral issues. He also volunteers for a variety of charitable organizations, serving as a member of The Berklee College of Music Board of Trustees and the University of Virginia McIntire Foundation Board of Trustees. Mr. Connaughton received a bachelor’s of science degree in commerce from the University of Virginia and an MBA from Harvard Business School, where he was a Baker Scholar. Mr. Connaughton serves as a member of the Leadership Development and Compensation Committee.

How do I contact John Connaughton?: The corporate mailing address for Mr. Connaughton and other IQVIA executives is 4820 EMPEROR BOULEVARD, DURHAM NC, 27703. IQVIA can also be reached via phone at (919) 998-2000 and via email at [email protected]. Learn More on John Connaughton's contact information.
Has John Connaughton been buying or selling shares of IQVIA?: John Connaughton has not been actively trading shares of IQVIA during the last ninety days. Most recently, John Connaughton sold 555,094 shares of the business's stock in a transaction on Monday, November 29th. The shares were sold at an average price of $262.60, for a transaction totalling $145,767,684.40. Learn More on John Connaughton's trading history.
Who are IQVIA's active insiders?: IQVIA's insider roster includes Ari Bousbib (Insider), Ronald Bruehlman (Insider), John Connaughton (Director), John Danhakl (Director), Kevin Knightly (Insider), Michael McDonnell (CFO), Ronald Rittenmeyer (Director), and Eric Sherbet (Insider). Learn More on IQVIA's active insiders.
Are insiders buying or selling shares of IQVIA?: In the last year, insiders at the medical research company sold shares 4 times. They sold a total of 42,585 shares worth more than $10,651,231.53. The most recent insider tranaction occured on August, 27th when insider Eric Sherbet sold 1,300 shares worth more than $320,229.00. Insiders at IQVIA own 1.6% of the company. Learn More about insider trades at IQVIA.
Information on this page was last updated on 8/27/2024.

John Connaughton Insider Trading History at IQVIA

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
11/29/2021	Sell	555,094	$262.60	$145,767,684.40
2/13/2020	Sell	703,828	$164.30	$115,638,940.40
6/15/2018	Sell	1,441,236	$103.00	$148,447,308.00
11/30/2017	Sell	1,163,191	$102.00	$118,645,482.00
9/19/2017	Sell	1,030,429	$94.87	$97,756,799.23

John Connaughton Buying and Selling Activity at IQVIA

IQVIA Company Overview

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

Today's Range

Now: $198.53

$195.27

$198.78

50 Day Range

MA: $211.07

$191.19

$236.61

2 Week Range

Now: $198.53

$187.62

$261.73

Volume

231,358 shs

Average Volume

1,186,569 shs

Market Capitalization

$36.03 billion

P/E Ratio

25.81

Dividend Yield

N/A

Beta

1.49